• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.

作者信息

Bian Li, Zhang Shaohua, Li Man, Yang Jin, Yin Yongmei

机构信息

Department of Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.

Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.

出版信息

Transl Breast Cancer Res. 2025 Jul 23;6:29. doi: 10.21037/tbcr-25-32. eCollection 2025.

DOI:10.21037/tbcr-25-32
PMID:40756953
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314681/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5470/12314681/b29450fa729d/tbcr-06-29-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5470/12314681/046427731ac2/tbcr-06-29-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5470/12314681/b29450fa729d/tbcr-06-29-f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5470/12314681/046427731ac2/tbcr-06-29-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5470/12314681/b29450fa729d/tbcr-06-29-f2.jpg

相似文献

1
Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04.抗体药物偶联物联合免疫疗法作为转移性三阴性乳腺癌一线治疗方案在ASCENT-04研究中的精准靶向细胞毒性作用
Transl Breast Cancer Res. 2025 Jul 23;6:29. doi: 10.21037/tbcr-25-32. eCollection 2025.
2
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study.来自ASCENT研究的高体重指数与戈沙妥珠单抗在转移性三阴性乳腺癌患者中的安全性和疗效的关联。
ESMO Open. 2025 Jun;10(6):105294. doi: 10.1016/j.esmoop.2025.105294. Epub 2025 Jun 2.
3
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
4
Effectiveness of sacituzumab govitecan and management of neutropenia in patients with metastatic triple-negative breast cancer treated in real-world settings in the United States.在美国真实世界环境中接受治疗的转移性三阴性乳腺癌患者中，戈沙妥珠单抗的疗效及中性粒细胞减少的管理。
ESMO Open. 2025 Jun;10(6):105308. doi: 10.1016/j.esmoop.2025.105308. Epub 2025 Jun 5.
5
Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study.转移性三阴性乳腺癌中的 sacituzumab-govitecan：一项多中心有效性和安全性研究。
Future Oncol. 2024;20(33):2565-2572. doi: 10.1080/14796694.2024.2394408. Epub 2024 Sep 12.
6
Exposure-Response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients With Metastatic Triple-Negative Breast Cancer.戈沙妥珠单抗治疗转移性三阴性乳腺癌患者疗效与安全性的暴露-反应分析
Clin Pharmacol Ther. 2025 Feb;117(2):570-578. doi: 10.1002/cpt.3495. Epub 2024 Nov 14.
7
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2- Metastatic Breast Cancer Data From the Phase 3 TROPiCS-02 Trial.戈沙妥珠单抗群体药代动力学：使用3期TROPiCS-02试验中HR+/HER2-转移性乳腺癌数据的更新分析
Clin Transl Sci. 2025 Jul;18(7):e70291. doi: 10.1111/cts.70291.
8
Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.依维莫司联合免疫检查点抑制剂治疗和化疗用于一线转移性三阴性乳腺癌可触发肿瘤微环境中巨噬细胞的重编程、免疫激活和细胞外基质重构。
J Immunother Cancer. 2024 Aug 30;12(8):e009160. doi: 10.1136/jitc-2024-009160.
9
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.帕博利珠单抗单药或联合治疗转移性三阴性乳腺癌患者的疗效和安全性：随机对照试验的系统评价和荟萃分析。
Curr Gene Ther. 2024;25(1):72-88. doi: 10.2174/0115665232283880240301035621.
10
Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.免疫疗法联合化疗治疗转移性三阴性乳腺癌：随机临床试验的系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2021 Dec;168:103530. doi: 10.1016/j.critrevonc.2021.103530. Epub 2021 Nov 18.

本文引用的文献

1
Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review.抗体药物偶联物在晚期三阴性乳腺癌治疗中的进展：一项叙述性综述。
Transl Breast Cancer Res. 2025 Jan 21;6:9. doi: 10.21037/tbcr-24-38. eCollection 2025.
2
Trop2-targeted therapy in breast cancer.针对Trop2的乳腺癌治疗
Biomark Res. 2024 Aug 13;12(1):82. doi: 10.1186/s40364-024-00633-6.
3
Expert consensus on the clinical application of immunotherapy in breast cancer: 2024.2024年乳腺癌免疫治疗临床应用专家共识
Transl Breast Cancer Res. 2024 Apr 29;5:9. doi: 10.21037/tbcr-24-15. eCollection 2024.
4
TORCHLIGHT trial, brightening the life of more patients with advanced triple-negative breast cancer.火炬之光试验，照亮更多晚期三阴性乳腺癌患者的生命。
Transl Breast Cancer Res. 2023 Sep 22;5:1. doi: 10.21037/tbcr-23-33. eCollection 2024.
5
Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer.晚期三阴性乳腺癌治疗现状及建议的叙述性综述
Transl Breast Cancer Res. 2022 Apr 30;3:17. doi: 10.21037/tbcr-22-12. eCollection 2022.
6
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.抗 PD-1/VEGF-A 双特异性抗体 ivonescimab（AK112/SMT112）在晚期实体瘤患者中的 1a 期剂量递增研究。
J Immunother Cancer. 2024 Apr 19;12(4):e008037. doi: 10.1136/jitc-2023-008037.
7
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.三阴性乳腺癌中的肿瘤浸润淋巴细胞。
JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056.
8
Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities.肿瘤突变负担预测癌症 PD-(L)1 阻断疗效：挑战与机遇。
Ann Oncol. 2024 Jun;35(6):508-522. doi: 10.1016/j.annonc.2024.03.007. Epub 2024 Mar 26.
9
Exploring the next generation of antibody-drug conjugates.探索下一代抗体药物偶联物。
Nat Rev Clin Oncol. 2024 Mar;21(3):203-223. doi: 10.1038/s41571-023-00850-2. Epub 2024 Jan 8.
10
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.特泊替尼联合白蛋白紫杉醇用于转移性或复发性三阴性乳腺癌：一项随机 3 期试验。
Nat Med. 2024 Jan;30(1):249-256. doi: 10.1038/s41591-023-02677-x. Epub 2024 Jan 8.